GlassScriptPhysician profile
Dayna F Mohammadione
NPI 1871595801
$2,603.12
in general payments reported to CMS, 2019-2025
35 companies · $623 in 2025
The $623 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $49.64 · 2021: $91.64 · 2022: $451 · 2023: $676 · 2024: $333 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.86 |
| Education | $193.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $483.37 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $220.76 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $192.15 | 2023-2025 | Myfembree |
| Abbvie INC. | $189.29 | 2019-2024 | |
| Organon LLC | $178.66 | 2021-2025 | Nexplanon |
| Exeltis, USA INC. | $155.61 | 2021-2025 | Slynd |
| Pfizer INC. | $138.96 | 2019-2024 | |
| Amgen INC. | $108.67 | 2019-2024 | Evenity, Prolia |
| Novo Nordisk INC | $103.66 | 2020-2025 | Wegovy |
| Sage Therapeutics, LLC | $76.66 | 2024-2025 | Zurzuvae |
| Allergan, INC. | $75.19 | 2019 | |
| Myovant Sciences INC. | $66.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $63.53 | 2019-2025 | Gardasil 9 |
| Daiichi Sankyo INC. | $58.52 | 2022-2023 | Injectafer |
| Therapeuticsmd, INC. | $58.20 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $47.09 | 2023-2025 | Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $41.05 | 2023 | Exparel |
| Mayne Pharma Commercial LLC | $40.90 | 2023-2025 | |
| Agile Therapeutics, INC. | $31.82 | 2022 | |
| Mylan Pharmaceuticals INC. | $29.29 | 2019-2022 | |
| Hologic Sales and Service, LLC | $25.30 | 2019 | |
| Coopersurgical, INC. | $21.70 | 2025 | Paragard T 380a |
| Supernus Pharmaceuticals, INC. | $19.83 | 2025 | Qelbree |
| Dexcom, INC. | $19.75 | 2025 | Dexcom G6 Transmitter |
| Millicent US INC | $17.84 | 2025 | Femlyv |
| Amag Pharmaceuticals, INC. | $17.60 | 2019 | |
| Gynesonics, INC. | $16.73 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Vertex Pharmaceuticals Incorporated | $16.32 | 2025 | |
| Optumhealth Care Solutions, LLC | $13.48 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Avion Pharmaceuticals | $13.35 | 2022 | |
| Duchesnay USA Incorporated | $13.29 | 2019 | |
| Evofem Biosciences, INC. | $13.11 | 2022 | |
| Minerva Surgical, INC | $11.91 | 2019 | |
| Tactile Systems Technology INC | $11.88 | 2019 | |
| Lupin INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dayna Mohammadione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.